Bausch Health Companies (NYSE: BHC) reported Q2 revenue for the quarter came in at $2.13 billion.

• Revenues of $2.128 Billion
• GAAP Net Loss of $873 Million
• GAAP Cash Flow from Operations of $222 Million
• Adjusted EBITDA (non-GAAP)1 of $868 Million
• Delivered Second Consecutive Quarter of Overall Organic Revenue Growth2, Driven by the Salix and Bausch + Lomb/International Segments3
• XIFAXAN® Revenue Increased by 26% Compared to the Second Quarter of 2017
• Maintained Revenue Guidance Range and Raised Full-Year Adjusted EBITDA (non-GAAP) Guidance Range

"For a second consecutive quarter, the Company delivered overall organic growth2, driven by solid results in our Salix and Bausch + Lomb/International segments, which together represented approximately 78% of our business in the quarter," said Joseph C. Papa, chairman and CEO, Bausch Health. "Growth in the Salix segment reflects higher sales of our promoted brands, most notably XIFAXAN® and RELISTOR®, while organic growth2 in the Bausch + Lomb/International segment was primarily due to volume increases and strong growth across Europe and China."

"Due to our strong results in the quarter, we are raising our full-year Adjusted EBITDA (non-GAAP) guidance range, and despite significant foreign exchange headwinds, we are maintaining our full-year revenue guidance range," continued Mr. Papa.

GUIDANCE:

Bausch Health Companies sees FY2018 revenue of $8.15-8.35 billion.

Full-Year Adjusted EBITDA (non-GAAP) in the range of $3.20 – $3.35 billion from $3.15 – $3.30 billion

For earnings history and earnings-related data on Bausch Health Companies (BHC) click here.